RPG Life Sciences Ltd Q2 FY26 | The RPG Baby That Outgrew Its Diapers – 21 % OPM, 33 % ROCE, Zero Debt, CFO Gone!
1. At a Glance
The RPG Group’s quiet little pharma arm just dropped its Q2 FY26 prescription: ₹ 182 crore revenue (+7.6 % QoQ), ₹ 28.5 crore PAT (+38 % QoQ), and margins tighter than an auditor’s smile — a healthy 21 % OPM and 32.8 % ROCE. Market cap ₹ 3,767 crore, stock at ₹ 2,278, PE ≈ 34, Book Value ₹ 335, Dividend Yield 0.9 %. Zero debt, 25 % ROE, 266× interest coverage — this one doesn’t borrow, it levitates.
But of course, no good quarter ends without some boardroom masala: the CFO resigned right after results. Coincidence? Investors are still deciding whether to clap or call HR.
From being RPG Group’s shy cousin behind CEAT tyres and KEC transmission towers, RPG Life is now a ₹ 660 crore-a-year, zero-leverage cash-cow selling Azoran and Mofetyl instead of miracles.
2. Introduction
If pharma were a family dinner, RPG Life Sciences would be the polite middle child — never topping exams like Sun Pharma but always turning in assignments on time. While sibling CEAT skids and KEC wires, RPG Life just grinds APIs and formulations, minting 25 % ROE and quietly mailing dividends.
It started as a joint venture with G.D. Searle (remember Lomotil? Yes, that one you took in college hostel emergencies). When Searle packed its bags, RPG Life decided to do both — the research and the rescue. Today it runs three divisions — Domestic Formulations (66 %), International Formulations (19 %) and APIs (15 %) — all profit-positive and surprisingly drama-free.
Until, of course, the CFO decided October 23 was a good day to quit. Maybe he was bored. Maybe he finished the turnaround early. Or maybe the upcoming MD handover from Yugal Sikri to Ashok Nair needed a fresh spreadsheet scent.
Either way, this is not a penny-stock circus; this is a grown-up pharma player wearing a blazer and cracking dad jokes in compliance meetings.
3. Business Model – WTF Do They Even Do?
Think of RPG Life as a two-storey pharma house: formulations upstairs, APIs in the basement, and digital sales humming in the kitchen.
Domestic Formulations (DF) – 66 % revenue Branded prescription drugs across nephrology, rheumatology, oncology, gastro, and cardio-diabeto. Flagships include Azoran, Mofetul, Naprosyn, HerMab, SacuNew, and that eternal legend Lomotil. India + Nepal footprint.
International Formulations (IF) – 19 % revenue Exports to Canada, Europe, ANZ, South America, Africa & Myanmar. They sell both branded generics (Azoran, Arpimune ME) and plain generics (Nicorandil, Sertraline).
APIs Division – 15 % revenue Focus on niche molecules: Azathioprine, Risperidone, Nicorandil, Pantoprazole. Basically, the backstage artists behind other people’s blockbuster drugs.
RPG Serv App – because no corporate deck is complete without “digital transformation.” 90 k+ doctors on board; 10 versions for 10 segments. Probably more downloads than half the Ayush apps on Play Store.
Integrated supply chain, GMP-certified facilities, global approvals, and just enough jargon to scare interns — that’s RPG Life’s prescription for predictability.
4. Financials Overview
Source table
Metric
Latest Qtr (Q2 FY26)
YoY (Q2 FY25)
Prev Qtr (Q1 FY26)
YoY %
QoQ %
Revenue (₹ Cr)
182
172
169
+5.8 %
+7.6 %
EBITDA (₹ Cr)
39
46
35
-15 %
+11 %
PAT (₹ Cr)
28.5
27
26
+5 %
+10 %
EPS (₹)
22.3
21.1
15.9
+6 %
+40 %
Annualised EPS: ≈ ₹ 130 → P/E ≈ 34.
Commentary: Margins remain a beautiful 21 %, debt = zero, and the only leverage visible is brand equity. QoQ growth steady, not sexy. The kind of quarter analysts call “boringly good.”
